Mast Therapeutics, Inc. (MSTX) grew with the stock adding 7.37% or $0 to close at $0.1 on light trading volume of 6.72M compared its three months average trading volume of 7.39M. The San Diego California 92130 based company operating under the Biotechnology industry has been trending down for the last 52 weeks, with the shares price now -76.28% down for the period and up by 17.51% so far this year. With price target of $2.75 and a 45.71% rebound from 52-week low, Mast Therapeutics, Inc. has plenty of upside potential, making it a hold with a view buy.
Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for serious or life-threatening diseases with significant unmet needs. The companys lead product candidate is MST-188 (vepoloxamer), an injection used for the treatment of sickle cell disease, arterial disease, and heart failure. It also develops AIR001, a sodium nitrite solution for intermittent inhalation via nebulizer, as well as for the treatment of heart failure with preserved ejection fraction. The company was formerly known as ADVENTRX Pharmaceuticals, Inc. and changed its name to Mast Therapeutics, Inc. in March 2013. Mast Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Bristol-Myers Squibb Company (BMY) dropped $-0.31 to close the day at a new closing price of $59.14, a -0.52% decrease in value from its previous closing price that moved the stock 20.62% above its 52 week low of $49.03. A total of 6.7M shares exchanged hands during the day compared with its three month average trading volume of 11.63M. The stock, which fluctuated between $59.03 and $59.75 during the day, currently situated -22.78% below its 52 week high. The stock is up by 5.68% in the past one month and up by 7.86% over the past three months. With a one year target estimate of $62.53 and RSI of 63.81, the stock still has upside potential, making it a hold for now.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung and renal cell cancer, and melanoma; Sprycel, a tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for metastatic melanoma; Abilify, an antipsychotic agent for adults with schizophrenia, bipolar mania disorder, and depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company has a clinical trial collaboration with Calithera Biosciences, Inc. to evaluate Opdivo in combination with Calitheras CB-839 in patients with clear cell renal cell carcinoma. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Chevron Corporation (CVX) shares were down in last trading by -0.03% to $117.82. It experienced lighter than average volume on day. The stock decreased in value by almost -0.34% over the past week and grew 4.27% in the past month. It is currently trading 6.51% above its 50 day moving average and 15.55% above its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -0.99% decrease in value from its one year high of $119. The RSI indicator value of 68.66, lead us to believe that it is a hold for now.
Chevron Corporation, through its subsidiaries, engages in integrated energy, chemicals, and petroleum operations worldwide. The company operates in two segments, Upstream and Downstream. The Upstream segment is involved in the exploration, development, and production of crude oil and natural gas; processing, liquefaction, transportation, and regasification associated with liquefied natural gas; transportation of crude oil through pipelines; and transportation, storage, and marketing of natural gas, as well as operates a gas-to-liquids plant. The Downstream segment engages in refining crude oil into petroleum products; marketing crude oil and refined products; transporting crude oil and refined products through pipeline, marine vessel, motor equipment, and rail car; and manufacturing and marketing commodity petrochemicals, and fuel and lubricant additives, as well as plastics for industrial uses. It is also involved in the cash management and debt financing activities; corporate administrative operations; insurance operations; real estate activities; and technology businesses. Further, the company holds interests in power plants, as well as operates geothermal plants; and engages in the transportation of refined products primarily in the coastal waters of the United States. The company was formerly known as ChevronTexaco Corporation and changed its name to Chevron Corporation in 2005. Chevron Corporation was founded in 1879 and is headquartered in San Ramon, California.